Physician profile
Royal Park
NPI 1336192301
$12,656.57
in general payments reported to CMS, 2019-2025
57 companies · $2,009 in 2025
The $2,009 reported for 2025 was more than what 80% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $567 · 2021: $1,955 · 2022: $2,519 · 2023: $1,957 · 2024: $2,734 · 2025: $2,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,275 · Travel and Lodging: $337 · Education: $89.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,274.82 |
| Travel and Lodging | $336.61 |
| Education | $89.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sn Holdings, LLC | $1,582.65 | 2021-2023 | |
| Astellas Pharma US INC | $1,220.66 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Dendreon Pharmaceuticals LLC | $1,130.21 | 2019-2025 | Provenge |
| Abbvie INC. | $934.33 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $849.85 | 2019-2025 | |
| Teleflex LLC | $809.97 | 2021-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $742.55 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $593.05 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $586.08 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $370.08 | 2019-2025 | Yonsa |
| Merck Sharp & Dohme LLC | $344.01 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $293.83 | 2022-2025 | |
| Tolmar, INC. | $264.54 | 2023-2025 | Eligard |
| Blue Earth Diagnostics | $223.76 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $208.23 | 2021-2025 | Lynparza |
Show all 56 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,021,343.05 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Royal Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.